Semaglutide oral vs injection: what actually changes between the two forms

Free consultation, reviewed the same day by a GPhC-registered Independent Prescriber — a real clinician, not an automated system
Free prescription and treatment dispatched the same day if clinically approved (order before 12pm, Monday to Friday)
Free next-working-day tracked delivery by DPD, in plain unbranded packaging
Priority aftercare available seven days a week, with no subscription and no hidden costs

The oral and injectable forms of semaglutide for weight management are both licensed in the UK and work through the same GLP-1 receptor pathway, but their dosing schedules, practical routines and trial results differ in meaningful ways. The tablet (Wegovy, approved by the MHRA on 11 June 2026) reaches a 25mg daily maintenance dose; the injection (also Wegovy) reaches 2.4mg weekly, with a higher 7.2mg dose now also approved. Neither is a prescription you can obtain without a clinical assessment — a GPhC-registered prescriber reviews your suitability before any treatment is dispensed.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

The key differences between semaglutide as a tablet and as a weekly injection

The myth worth clearing up first: the tablet is not a weaker version

A common assumption is that swallowing a pill must deliver less than an injection straight under the skin. The doses look wildly different (25mg by mouth against 2.4mg subcutaneously) so the gap seems to confirm it. In practice, oral semaglutide has very low gut absorption, which is why the tablet dose is so much higher; the delivered amount reaching your bloodstream is calibrated to produce a meaningful clinical effect. You can read more about how the tablet form works on our oral semaglutide overview page.

The OASIS 4 phase 3 trial (307 adults, 64 weeks, alongside lifestyle changes) recorded an average weight reduction of around 13.6% on the 25mg tablet versus roughly 2.4% on placebo. Among participants who stayed fully adherent, the average rose to approximately 16.6%. The injectable form's STEP 1 trial (68 weeks, 2.4mg) showed around 15% average reduction, as reported in the New England Journal of Medicine. Those figures are close enough that the choice between them is rarely settled by the headline number alone.

What changes more substantially is the practical experience: daily timing rules, fridge storage, needle technique. If you are unsure whether semaglutide comes as an oral tablet or an injection, our dedicated page explains exactly how each form is administered and why both routes exist. Our page on whether oral semaglutide matches the injection on effectiveness goes deeper into how those figures translate to real-world use.

Routine and storage: where the two forms genuinely feel different day to day

The injection is taken once a week. The pen lives in the fridge door, retrieved briefly, brought to room temperature and administered at whatever day of the week you choose. Many people find a regular weekly slot (Sunday evening, say, or Monday morning) becomes habit quickly. Sharps disposal is a practical consideration worth planning for at the outset.

The tablet has a stricter daily ritual. It is taken first thing in the morning, on a completely empty stomach, with a small amount of plain water (up to around 120ml), and you wait at least 30 minutes before any food, coffee or other oral medicines. Miss that window and you will need to try again the next morning. No refrigeration is required, the tablet is room-temperature stable, which makes it more travel-friendly than the pen and suits people who find fridge management awkward.

For a fuller breakdown of day-to-day practicalities, the comparison on our semaglutide tablets vs injection page covers both forms side by side. If you are weighing the two forms specifically around whether tablets work as well, this page addresses that question directly.

Eligibility, licensing and the comparison in plain numbers

Both forms carry a Black Triangle (▼) designation, meaning the MHRA monitors them with extra vigilance. Both are licensed for adults, not under-18s, and neither is recommended during pregnancy, while breastfeeding, or when trying to conceive.

The injection's licensed BMI thresholds are ≥30, or ≥27 with at least one weight-related condition. The tablet shares the same lower threshold (≥27 with a weight-related condition) but its ≥30 alone route is also available. Lower BMI thresholds apply for some ethnic backgrounds under NICE's appraisal of injectable semaglutide (TA875); the tablet's thresholds follow the MHRA licence rather than a NICE appraisal, as no appraisal existed at the time of writing. The MHRA's patient-level guidance on semaglutide is available on the NHS medicines pages and is worth reading alongside either form's Patient Information Leaflet.

The table below summarises the factual differences. Numbers are drawn from published trial data and MHRA licence documents.

FactorWegovy injection (semaglutide)Wegovy tablet (semaglutide)
Licensed in UKYes (weight management)Yes, from 11 June 2026 (weight management)
FrequencyOnce weeklyOnce daily
Maintenance dose2.4mg (7.2mg also approved)25mg
StorageRefrigerated (2–8°C)Room temperature, no fridge needed
Average weight loss (trial)~15% at 68 weeks (STEP 1, NEJM)~13.6% at 64 weeks (OASIS 4); ~16.6% in fully adherent group
NHS availabilityVia specialist services (NICE TA875)Not yet appraised by NICE; private prescription only at launch

Neither form has been declared superior for all patients, the evidence shows overlapping outcomes and different practical profiles. For anyone still deciding between the two options, our guide to semaglutide pills vs injection sets out the key considerations in one place to help you think it through before speaking to a prescriber. Which one fits your life, your medical history and your preferences is a clinical decision our prescribers make with you. You can explore both options on our treatment page, or read a broader overview of weight loss treatment approaches before starting a consultation.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions